{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T13:25:32Z","timestamp":1786886732138,"version":"build-2736575974"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T00:00:00Z","timestamp":1786838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T00:00:00Z","timestamp":1786838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04547-7","type":"journal-article","created":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T12:56:04Z","timestamp":1786884964000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictors of immunotherapy response in gastric cancer: the role of the tumor microenvironment and integrative predictive models"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7955-1625","authenticated-orcid":false,"given":"Elisaveta Andreevna","family":"Tsarenkova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2106-3513","authenticated-orcid":false,"given":"Anna Yuryevna","family":"Kalinchuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6637-4417","authenticated-orcid":false,"given":"Elena Olegovna","family":"Shmakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1195-4008","authenticated-orcid":false,"given":"Sergey Vladimirovich","family":"Vtorushin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4737-8951","authenticated-orcid":false,"given":"Evgeniya Sergeevna","family":"Grigoryeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2061-8417","authenticated-orcid":false,"given":"Lyubov Aleksandrovna","family":"Tashireva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,16]]},"reference":[{"issue":"3","key":"4547_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2020","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2020;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"9856","key":"4547_CR2","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1016\/S0140-6736(12)60919-2","volume":"380","author":"I Soerjomataram","year":"2008","unstructured":"Soerjomataram I, Lortet-Tieulent J, Parkin DM, Ferlay J, Mathers C, Forman D, et al. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet. 2008;380(9856):1840\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(12)60919-2.","journal-title":"Lancet"},{"issue":"10","key":"4547_CR3","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):1005\u201320. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.004.","journal-title":"Ann Oncol"},{"issue":"9","key":"4547_CR4","doi-asserted-by":"publisher","first-page":"4575","DOI":"10.21873\/anticanres.10123","volume":"35","author":"P Chrom","year":"2015","unstructured":"Chrom P, Stec R, Szczylik C. Second-line treatment of advanced gastric cancer: current options and future perspectives. Anticancer Res. 2015;35(9):4575\u201383. https:\/\/doi.org\/10.21873\/anticanres.10123.","journal-title":"Anticancer Res"},{"issue":"10111","key":"4547_CR5","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10111):2461\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(17)31827-5.","journal-title":"Lancet"},{"issue":"5","key":"4547_CR6","doi-asserted-by":"publisher","first-page":"e180013","DOI":"10.1001\/jamaoncol.2018.0013","volume":"4","author":"CS Fuchs","year":"2018","unstructured":"Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018;4(5):e180013. https:\/\/doi.org\/10.1001\/jamaoncol.2018.0013.","journal-title":"JAMA Oncol"},{"key":"4547_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00763","volume":"10","author":"R Sundar","year":"2020","unstructured":"Sundar R, Smyth EC, Peng S, Yeong JPS, Tan P. Predictive biomarkers of immune checkpoint inhibition in gastroesophageal cancers. Front Oncol. 2020;10:763. https:\/\/doi.org\/10.3389\/fonc.2020.00763.","journal-title":"Front Oncol"},{"issue":"3","key":"4547_CR8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/bjs.10663","volume":"105","author":"K Polom","year":"2018","unstructured":"Polom K, Marano L, Marrelli D, De Luca R, Roviello G, Savelli V, et al. Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer. Br J Surg. 2018;105(3):159\u201367. https:\/\/doi.org\/10.1002\/bjs.10663.","journal-title":"Br J Surg"},{"issue":"10","key":"4547_CR9","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","volume":"6","author":"K Shitara","year":"2020","unstructured":"Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, et al. Efficacy and safety of Pembrolizumab or Pembrolizumab plus Chemotherapy vs Chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol. 2020;6(10):1571\u201380. https:\/\/doi.org\/10.1001\/jamaoncol.2020.3370.","journal-title":"JAMA Oncol"},{"issue":"10142","key":"4547_CR10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0140-6736(18)31257-1","volume":"392","author":"K Shitara","year":"2018","unstructured":"Shitara K, \u00d6zg\u00fcro\u011flu M, Bang YJ, Di Bartolomeo M, Mandal\u00e0 M, Ryu MH, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392(10142):123\u201333. https:\/\/doi.org\/10.1016\/S0140-6736(18)31257-1.","journal-title":"Lancet"},{"key":"4547_CR11","doi-asserted-by":"publisher","first-page":"4180517","DOI":"10.1155\/2018\/4180517","volume":"2018","author":"Y Wang","year":"2018","unstructured":"Wang Y, Zhu C, Song W, Li J, Zhao G, Cao H. PD-L1 Expression and CD8+ T cell infiltration predict a favorable prognosis in advanced gastric cancer. J Immunol Res. 2018;2018:4180517. https:\/\/doi.org\/10.1155\/2018\/4180517.","journal-title":"J Immunol Res"},{"key":"4547_CR12","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1038\/s41416-020-0793-y","volume":"122","author":"Y Kwak","year":"2020","unstructured":"Kwak Y, Koh J, Park Y, Hong Y, Park K, Kim H, et al. Differential prognostic impact of CD8+ T cells based on human leucocyte antigen I and PD-L1 expression in microsatellite-unstable gastric cancer. Br J Cancer. 2020;122:1399\u2013408. https:\/\/doi.org\/10.1038\/s41416-020-0793-y.","journal-title":"Br J Cancer"},{"issue":"9","key":"4547_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009603","volume":"12","author":"J Wang","year":"2024","unstructured":"Wang J, Liang Y, Xue A, Xiao J, Zhao X, Cao S, et al. Intratumoral CXCL13+ CD160+ CD8+ T cells promote the formation of tertiary lymphoid structures to enhance the efficacy of immunotherapy in advanced gastric cancer. J Immunother Cancer. 2024;12(9):e009603. https:\/\/doi.org\/10.1136\/jitc-2024-009603.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"4547_CR14","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1053\/j.gastro.2023.10.022","volume":"166","author":"C Hu","year":"2024","unstructured":"Hu C, You W, Kong D, Huang Y, Lu J, Zhao M, et al. Tertiary lymphoid structure-associated B cells enhance CXCL13+CD103+CD8+ tissue-resident memory T-cell response to programmed cell death protein 1 blockade in cancer immunotherapy. Gastroenterology. 2024;166(6):1069\u201384. https:\/\/doi.org\/10.1053\/j.gastro.2023.10.022.","journal-title":"Gastroenterology"},{"key":"4547_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1551259","volume":"16","author":"S Xu","year":"2025","unstructured":"Xu S, Li D, Ning T, Lu Y, Sun Y, Bai H, et al. High expression of CXCL13 predicts a favorable response to immunotherapy by upregulating CXCR5+CD8+ T-cell infiltration in gastric cancer. Front Immunol. 2025;16:1551259. https:\/\/doi.org\/10.3389\/fimmu.2025.1551259.","journal-title":"Front Immunol"},{"issue":"12","key":"4547_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010041","volume":"12","author":"Z Ji","year":"2024","unstructured":"Ji Z, Wang X, Xin J, Ma L, Zuo D, Li H, et al. Multiomics reveals tumor microenvironment remodeling in locally advanced gastric and gastroesophageal junction cancer following neoadjuvant immunotherapy and chemotherapy. J Immunother Cancer. 2024;12(12):e010041. https:\/\/doi.org\/10.1136\/jitc-2024-010041.","journal-title":"J Immunother Cancer"},{"issue":"14","key":"4547_CR17","doi-asserted-by":"publisher","first-page":"4476","DOI":"10.7150\/ijbs.87635","volume":"19","author":"Q Jiang","year":"2023","unstructured":"Jiang Q, Chen Z, Meng F, Zhang H, Chen H, Xue J, et al. CD36-BATF2\/MYB axis predicts anti-PD-1 immunotherapy response in gastric cancer. Int J Biol Sci. 2023;19(14):4476\u201392. https:\/\/doi.org\/10.7150\/ijbs.87635.","journal-title":"Int J Biol Sci"},{"issue":"5","key":"4547_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2025.103220","volume":"56","author":"A Ghorbani Ranjbary","year":"2025","unstructured":"Ghorbani Ranjbary A, Mehrzad J, Dehghani H, Hosseinkhani S. Impact of IL-17a on apoptosis and mucinosis-related molecules in the microenvironment of colorectal cancer. Arch Med Res. 2025;56(5):103220. https:\/\/doi.org\/10.1016\/j.arcmed.2025.103220.","journal-title":"Arch Med Res"},{"issue":"3","key":"4547_CR19","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1136\/gutjnl-2024-333617","volume":"74","author":"Y Li","year":"2025","unstructured":"Li Y, Zheng Y, Huang J, Nie RC, Wu QN, Zuo Z, et al. CAF-macrophage crosstalk in tumour microenvironments governs the response to immune checkpoint blockade in gastric cancer peritoneal metastases. Gut. 2025;74(3):350\u201363. https:\/\/doi.org\/10.1136\/gutjnl-2024-333617.","journal-title":"Gut"},{"issue":"23","key":"4547_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252312715","volume":"25","author":"J Zhang","year":"2024","unstructured":"Zhang J, Zhang M, Lou J, Wu L, Zhang S, Liu X, et al. Machine learning integration with single-cell transcriptome sequencing datasets reveals the impact of tumor-associated neutrophils on the immune microenvironment and immunotherapy outcomes in gastric cancer. Int J Mol Sci. 2024;25(23):12715. https:\/\/doi.org\/10.3390\/ijms252312715.","journal-title":"Int J Mol Sci"},{"key":"4547_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113002","volume":"141","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Wang W, Liu Q, Jiang J, Zhao P, Huang C, et al. CD19+CD73+ B cells infiltration indicates poor prognosis and unfavorable responses to immunotherapy in gastric cancer. Int Immunopharmacol. 2024;141:113002. https:\/\/doi.org\/10.1016\/j.intimp.2024.113002.","journal-title":"Int Immunopharmacol"},{"key":"4547_CR22","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/nri2506","volume":"9","author":"DI Gabrilovich","year":"2009","unstructured":"Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162\u201374. https:\/\/doi.org\/10.1038\/nri2506.","journal-title":"Nat Rev Immunol"},{"key":"4547_CR23","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","volume":"12","author":"WH Fridman","year":"2012","unstructured":"Fridman WH, Pag\u00e8s F, Saut\u00e8s-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12:298\u2013306. https:\/\/doi.org\/10.1038\/nrc3245.","journal-title":"Nat Rev Cancer"},{"key":"4547_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.114180","volume":"158","author":"B Wang","year":"2023","unstructured":"Wang B, Zhang Z, Liu W, Tan B. Targeting regulatory T cells in gastric cancer: pathogenesis, immunotherapy, and prognosis. Biomed Pharmacother. 2023;158:114180. https:\/\/doi.org\/10.1016\/j.biopha.2022.114180.","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"4547_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010174","volume":"12","author":"H Shoji","year":"2024","unstructured":"Shoji H, Kudo-Saito C, Nagashima K, Imazeki H, Tsugaru K, Takahashi N, et al. Myeloid subsets impede the efficacy of anti-PD1 therapy in patients with advanced gastric cancer (WJOG10417GTR study). J Immunother Cancer. 2024;12(11):e010174. https:\/\/doi.org\/10.1136\/jitc-2024-010174.","journal-title":"J Immunother Cancer"},{"issue":"10","key":"4547_CR26","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1136\/gutjnl-2018-316324","volume":"68","author":"C Lin","year":"2019","unstructured":"Lin C, He H, Liu H, Li R, Chen Y, Qi Y, et al. Tumour-associated macrophages-derived CXCL8 determines immune evasion through autonomous PD-L1 expression in gastric cancer. Gut. 2019;68(10):1764\u201373. https:\/\/doi.org\/10.1136\/gutjnl-2018-316324.","journal-title":"Gut"},{"issue":"4","key":"4547_CR27","doi-asserted-by":"publisher","first-page":"e626","DOI":"10.1097\/SLA.0000000000004037","volume":"275","author":"H Zhang","year":"2022","unstructured":"Zhang H, Li R, Cao Y, Gu Y, Lin C, Liu X, et al. Poor clinical outcomes and immunoevasive contexture in intratumoral IL-10-producing macrophages enriched gastric cancer patients. Ann Surg. 2022;275(4):e626\u201335. https:\/\/doi.org\/10.1097\/SLA.0000000000004037.","journal-title":"Ann Surg"},{"issue":"14","key":"4547_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17142407","volume":"17","author":"LA Tashireva","year":"2025","unstructured":"Tashireva LA, Kalinchuk AY, Shmakova EO, Tsarenkova EA, Loos DM, Iamschikov P, et al. PD-1-positive CD8+ T cells and PD-1-positive FoxP3+ cells in tumor microenvironment predict response to neoadjuvant chemoimmunotherapy in gastric cancer patients. Cancers (Basel). 2025;17(14):2407. https:\/\/doi.org\/10.3390\/cancers17142407.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4547_CR29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13046-019-1514-3","volume":"39","author":"K Yuan","year":"2020","unstructured":"Yuan K, Ye J, Liu Z, Ren Y, He W, Xu J, et al. Complement C3 overexpression activates JAK2\/STAT3 pathway and correlates with gastric cancer progression. J Exp Clin Cancer Res. 2020;39(1):9. https:\/\/doi.org\/10.1186\/s13046-019-1514-3.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"4547_CR30","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s13402-023-00849-y","volume":"47","author":"R Wei","year":"2024","unstructured":"Wei R, Song J, Liu X, Huo S, Liu C, Liu X. Immunosuppressive MFAP2+ cancer associated fibroblasts conferred unfavorable prognosis and therapeutic resistance in gastric cancer. Cell Oncol (Dordr). 2024;47(1):55\u201368. https:\/\/doi.org\/10.1007\/s13402-023-00849-y.","journal-title":"Cell Oncol (Dordr)"},{"issue":"1","key":"4547_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57465-7","volume":"16","author":"J Song","year":"2025","unstructured":"Song J, Wei R, Liu C, Zhao Z, Liu X, Wang Y, et al. Antigen-presenting cancer associated fibroblasts enhance antitumor immunity and predict immunotherapy response. Nat Commun. 2025;16(1):2175. https:\/\/doi.org\/10.1038\/s41467-025-57465-7.","journal-title":"Nat Commun"},{"key":"4547_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.980986","volume":"13","author":"S Jiang","year":"2022","unstructured":"Jiang S, Ding X, Wu Q, Cheng T, Xu M, Huang J. Identifying immune cells-related phenotype to predict immunotherapy and clinical outcome in gastric cancer. Front Immunol. 2022;13:980986. https:\/\/doi.org\/10.3389\/fimmu.2022.980986.","journal-title":"Front Immunol"},{"issue":"1","key":"4547_CR33","doi-asserted-by":"publisher","first-page":"4851","DOI":"10.1038\/s41467-022-32570-z","volume":"13","author":"Y Chen","year":"2022","unstructured":"Chen Y, Jia K, Sun Y, Zhang C, Li Y, Zhang L, et al. Predicting response to immunotherapy in gastric cancer via multi-dimensional analyses of the tumour immune microenvironment. Nat Commun. 2022;13(1):4851. https:\/\/doi.org\/10.1038\/s41467-022-32570-z.","journal-title":"Nat Commun"},{"issue":"10","key":"4547_CR34","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/j.ajpath.2023.06.004","volume":"193","author":"Z Wei","year":"2023","unstructured":"Wei Z, Zhao X, Chen J, Sun Q, Wang Z, Wang Y, et al. Deep learning-based stratification of gastric cancer patients from hematoxylin and eosin-stained whole slide images by predicting molecular features for immunotherapy response. Am J Pathol. 2023;193(10):1517\u201327. https:\/\/doi.org\/10.1016\/j.ajpath.2023.06.004.","journal-title":"Am J Pathol"},{"issue":"1","key":"4547_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0768-9","volume":"7","author":"AA Davis","year":"2019","unstructured":"Davis AA, Patel VG. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):278. https:\/\/doi.org\/10.1186\/s40425-019-0768-9.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"4547_CR36","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Guti\u00e9rrez E, et al. Relatlimab and Nivolumab versus Nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386(1):24\u201334. https:\/\/doi.org\/10.1056\/NEJMoa2109970.","journal-title":"N Engl J Med"},{"issue":"1","key":"4547_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-022-00794-w","volume":"27","author":"L Guo","year":"2022","unstructured":"Guo L, Liu D. Identification of RFX5 as prognostic biomarker and associated with immune infiltration in stomach adenocarcinoma. Eur J Med Res. 2022;27(1):164. https:\/\/doi.org\/10.1186\/s40001-022-00794-w.","journal-title":"Eur J Med Res"},{"issue":"1","key":"4547_CR38","doi-asserted-by":"publisher","first-page":"221","DOI":"10.26355\/eurrev_202401_34907","volume":"28","author":"X Yan","year":"2024","unstructured":"Yan X, Huan J. CSK may be a potential prognostic biomarker reflecting the immune status of gastric cancer. Eur Rev Med Pharmacol Sci. 2024;28(1):221\u201330. https:\/\/doi.org\/10.26355\/eurrev_202401_34907.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"10","key":"4547_CR39","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1002\/cac2.12476","volume":"43","author":"B Zhang","year":"2023","unstructured":"Zhang B, Wang CM, Wu HX, Wang F, Chai YY, Hu Y, et al. MFSD2A potentiates gastric cancer response to anti-PD-1 immunotherapy by reprogramming the tumor microenvironment to activate T cell response. Cancer Commun. 2023;43(10):1097\u2013116. https:\/\/doi.org\/10.1002\/cac2.12476.","journal-title":"Cancer Commun"},{"issue":"1","key":"4547_CR40","doi-asserted-by":"publisher","first-page":"63","DOI":"10.21037\/jgo-23-984","volume":"15","author":"H Zhang","year":"2024","unstructured":"Zhang H, Liu R, Chen Y, Ma R, Xue Q, Sahu A, et al. The prognostic value and potential immunotherapeutic efficacy of ACVR1 in treating gastric cancer. J Gastrointest Oncol. 2024;15(1):63\u201385. https:\/\/doi.org\/10.21037\/jgo-23-984.","journal-title":"J Gastrointest Oncol"},{"key":"4547_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1545605","volume":"16","author":"X Wu","year":"2025","unstructured":"Wu X, Hou S, Ye Y, Gao Z. CXCR2P1 enhances the response of gastric cancer to PD-1 inhibitors through increasing the immune infiltration of tumors. Front Immunol. 2025;16:1545605. https:\/\/doi.org\/10.3389\/fimmu.2025.1545605.","journal-title":"Front Immunol"},{"issue":"1","key":"4547_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-39784-1","volume":"13","author":"F Liu","year":"2023","unstructured":"Liu F, Liu J, Shi X, Hu X, Wei L, Huo B, et al. Identification of INHBA as a potential biomarker for gastric cancer through a comprehensive analysis. Sci Rep. 2023;13(1):12494. https:\/\/doi.org\/10.1038\/s41598-023-39784-1.","journal-title":"Sci Rep"},{"issue":"1","key":"4547_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-11878-7","volume":"24","author":"Z Hong","year":"2024","unstructured":"Hong Z, Wen P, Wang K, Wei X, Xie W, Rao S, et al. The macrophage-associated prognostic gene ANXA5 promotes immunotherapy resistance in gastric cancer through angiogenesis. BMC Cancer. 2024;24(1):141. https:\/\/doi.org\/10.1186\/s12885-024-11878-7.","journal-title":"BMC Cancer"},{"key":"4547_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2023.107406","volume":"166","author":"D Zhang","year":"2023","unstructured":"Zhang D, Sun R, Di C, Li L, Zhao F, Han Y, et al. Microdissection of cancer-associated fibroblast infiltration subtypes unveils the secreted SERPINE2 contributing to immunosuppressive microenvironment and immuotherapeutic resistance in gastric cancer: a large-scale study integrating bulk and single-cell transcriptome profiling. Comput Biol Med. 2023;166:107406. https:\/\/doi.org\/10.1016\/j.compbiomed.2023.107406.","journal-title":"Comput Biol Med"},{"issue":"4","key":"4547_CR45","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s10620-025-08882-7","volume":"70","author":"Z Yang","year":"2025","unstructured":"Yang Z, Yu B, Hu J, Jiang L, Jian M. LRRC25 is a potential biomarker for predicting immunotherapy response in patients with gastric cancer. Dig Dis Sci. 2025;70(4):1395\u2013410. https:\/\/doi.org\/10.1007\/s10620-025-08882-7.","journal-title":"Dig Dis Sci"},{"issue":"10","key":"4547_CR46","doi-asserted-by":"publisher","first-page":"8944","DOI":"10.18632\/aging.205850","volume":"16","author":"G Li","year":"2024","unstructured":"Li G, Li Q, Ping M, Jiao Z, Wang X, Cheng J, et al. SLAMF8 can predict prognosis of pan-cancer and the immunotherapy response effectivity of gastric cancer. Aging (Albany NY). 2024;16(10):8944\u201364. https:\/\/doi.org\/10.18632\/aging.205850.","journal-title":"Aging (Albany NY)"},{"key":"4547_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1578068","volume":"16","author":"LD Sun","year":"2025","unstructured":"Sun LD, Zhang LL, Wan Z, Yang XD, Yao J, Yang ZL, et al. TNFRSF12A expression in stomach adenocarcinoma and its preliminary role in predicting immunotherapy response. Front Immunol. 2025;16:1578068. https:\/\/doi.org\/10.3389\/fimmu.2025.1578068.","journal-title":"Front Immunol"},{"issue":"2","key":"4547_CR48","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003663","volume":"10","author":"X Bai","year":"2022","unstructured":"Bai X, Wong CC, Pan Y, Chen H, Liu W, Zhai J, et al. Loss of YTHDF1 in gastric tumors restores sensitivity to antitumor immunity by recruiting mature dendritic cells. J Immunother Cancer. 2022;10(2):e003663. https:\/\/doi.org\/10.1136\/jitc-2021-003663.","journal-title":"J Immunother Cancer"},{"issue":"9","key":"4547_CR49","doi-asserted-by":"publisher","DOI":"10.1177\/0300060520951405","volume":"48","author":"P Mo","year":"2020","unstructured":"Mo P, Xie S, Cai W, Ruan J, Du Q, Ye J, et al. N6-methyladenosine (m6A) RNA methylation signature as a predictor of stomach adenocarcinoma outcomes and its association with immune checkpoint molecules. J Int Med Res. 2020;48(9):0300060520951405. https:\/\/doi.org\/10.1177\/0300060520951405.","journal-title":"J Int Med Res"},{"issue":"1","key":"4547_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-73784-z","volume":"14","author":"Y Yu","year":"2024","unstructured":"Yu Y, Luo K, Liu M, Chen L, Gao X, Zhang L, et al. Comprehensive analysis reveals that P4HA3 is a prognostic and diagnostic gastric cancer biomarker that can predict immunotherapy efficacy. Sci Rep. 2024;14(1):22959. https:\/\/doi.org\/10.1038\/s41598-024-73784-z.","journal-title":"Sci Rep"},{"issue":"2","key":"4547_CR51","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s10120-024-01572-9","volume":"28","author":"R Su","year":"2025","unstructured":"Su R, Sun X, Luo Y, Gu L, Wang F, Dong A, et al. SUSD2+ cancer-associated fibroblasts in gastric cancer mediate the effect of immunosuppression and predict overall survival and the effectiveness of neoadjuvant immunotherapy. Gastric Cancer. 2025;28(2):245\u201363. https:\/\/doi.org\/10.1007\/s10120-024-01572-9.","journal-title":"Gastric Cancer"},{"issue":"8","key":"4547_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.labinv.2024.102090","volume":"104","author":"SY Wang","year":"2024","unstructured":"Wang SY, Yang XQ, Wang YX, Shen A, Liang CC, Huang RJ, et al. Overexpression of COX7A1 promotes the resistance of gastric cancer to oxaliplatin and weakens the efficacy of immunotherapy. Lab Invest. 2024;104(8):102090. https:\/\/doi.org\/10.1016\/j.labinv.2024.102090.","journal-title":"Lab Invest"},{"issue":"7","key":"4547_CR53","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00262-024-03716-3","volume":"73","author":"W Zhao","year":"2024","unstructured":"Zhao W, Liang Z, Yao Y, Ge Y, An G, Duan L, et al. GGT5: a potential immunoTIMEtherapy response inhibitor in gastric cancer by modulating GSH metabolism and sustaining memory CD8+ T cell infiltration. Cancer Immunol Immunother. 2024;73(7):131. https:\/\/doi.org\/10.1007\/s00262-024-03716-3.","journal-title":"Cancer Immunol Immunother"},{"issue":"13","key":"4547_CR54","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.7150\/thno.86928","volume":"13","author":"Y Lin","year":"2023","unstructured":"Lin Y, Jing X, Chen Z, Pan X, Xu D, Yu X, et al. Histone deacetylase-mediated tumor microenvironment characteristics and synergistic immunotherapy in gastric cancer. Theranostics. 2023;13(13):4574\u2013600. https:\/\/doi.org\/10.7150\/thno.86928.","journal-title":"Theranostics"},{"issue":"7637","key":"4547_CR55","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321\u201330. https:\/\/doi.org\/10.1038\/nature21349.","journal-title":"Nature"},{"issue":"5","key":"4547_CR56","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541\u201350. https:\/\/doi.org\/10.1038\/s41591-018-0014-x.","journal-title":"Nat Med"},{"issue":"3","key":"4547_CR57","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18(3):197\u2013218. https:\/\/doi.org\/10.1038\/s41573-018-0007-y.","journal-title":"Nat Rev Drug Discov"},{"issue":"7517","key":"4547_CR58","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202\u20139. https:\/\/doi.org\/10.1038\/nature13480.","journal-title":"Nature"},{"issue":"7693","key":"4547_CR59","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544\u20138. https:\/\/doi.org\/10.1038\/nature25501.","journal-title":"Nature"},{"issue":"8","key":"4547_CR60","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002467","volume":"9","author":"D Zeng","year":"2021","unstructured":"Zeng D, Wu J, Luo H, Li Y, Xiao J, Peng J, et al. Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer. J Immunother Cancer. 2021;9(8):e002467. https:\/\/doi.org\/10.1136\/jitc-2021-002467.","journal-title":"J Immunother Cancer"},{"key":"4547_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.890922","volume":"13","author":"Y Chen","year":"2022","unstructured":"Chen Y, Sun Z, Wan L, Chen H, Xi T, Jiang Y. Tumor microenvironment characterization for assessment of recurrence and survival outcome in gastric cancer to predict chemotherapy and immunotherapy response. Front Immunol. 2022;13:890922. https:\/\/doi.org\/10.3389\/fimmu.2022.890922.","journal-title":"Front Immunol"},{"issue":"11","key":"4547_CR62","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/j.medj.2024.07.006","volume":"5","author":"M Shi","year":"2024","unstructured":"Shi M, Zeng D, Luo H, Xiao J, Li Y, Yuan X, et al. Tumor microenvironment RNA test to predict immunotherapy outcomes in advanced gastric cancer: the TIMES001 trial. Med. 2024;5(11):1378-1392.e3. https:\/\/doi.org\/10.1016\/j.medj.2024.07.006.","journal-title":"Med"},{"issue":"1","key":"4547_CR63","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1200\/JCO.2017.74.9846","volume":"36","author":"T Doi","year":"2018","unstructured":"Doi T, Piha-Paul SA, Jalal SI, Saraf S, Lunceford J, Koshiji M, et al. Safety and antitumor activity of the anti-programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma. J Clin Oncol. 2018;36(1):61\u20137. https:\/\/doi.org\/10.1200\/JCO.2017.74.9846.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4547_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-09062-2","volume":"22","author":"L Lei","year":"2022","unstructured":"Lei L, Li N, Yuan P, Liu D. A new risk model based on a 11-m6A-related lncRNA signature for predicting prognosis and monitoring immunotherapy for gastric cancer. BMC Cancer. 2022;22(1):365. https:\/\/doi.org\/10.1186\/s12885-021-09062-2.","journal-title":"BMC Cancer"},{"issue":"6","key":"4547_CR65","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006920","volume":"11","author":"K Shitara","year":"2023","unstructured":"Shitara K, Di Bartolomeo M, Mandala M, Ryu MH, Caglevic C, Olesinski T, et al. Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial. J Immunother Cancer. 2023;11(6):e006920. https:\/\/doi.org\/10.1136\/jitc-2023-006920.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"4547_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12302-w","volume":"24","author":"S Wang","year":"2024","unstructured":"Wang S, Zhang W, Wu X, Zhu Z, Chen Y, Liu W, et al. Comprehensive analysis of T-cell regulatory factors and tumor immune microenvironment in stomach adenocarcinoma. BMC Cancer. 2024;24(1):570. https:\/\/doi.org\/10.1186\/s12885-024-12302-w.","journal-title":"BMC Cancer"},{"issue":"2","key":"4547_CR67","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/CJI.0000000000000539","volume":"48","author":"X Li","year":"2025","unstructured":"Li X, Tang B, Yujie O, Xu C, Yuan S. Single-cell RNA sequencing analysis reveals cancer-associated fibroblast signature for prediction of clinical outcomes and immunotherapy in gastric cancer. J Immunother. 2025;48(2):63\u201377. https:\/\/doi.org\/10.1097\/CJI.0000000000000539.","journal-title":"J Immunother"},{"issue":"10","key":"4547_CR68","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1097\/CAD.0000000000001651","volume":"35","author":"Q Peng","year":"2024","unstructured":"Peng Q, Zhang P, Liu G, Lu L. Integrated single-cell and bulk RNA sequencing analyses identify an immunotherapy nonresponse-related fibroblast signature in gastric cancer. Anticancer Drugs. 2024;35(10):952\u201368. https:\/\/doi.org\/10.1097\/CAD.0000000000001651.","journal-title":"Anticancer Drugs"},{"issue":"14","key":"4547_CR69","doi-asserted-by":"publisher","first-page":"3926","DOI":"10.1158\/1078-0432.CCR-20-2790","volume":"27","author":"M Lei","year":"2021","unstructured":"Lei M, Siemers NO, Pandya D, Chang H, Sanchez T, Harbison C, et al. Analyses of PD-L1 and inflammatory gene expression association with efficacy of nivolumab \u00b1 ipilimumab in gastric cancer\/gastroesophageal junction cancer. Clin Cancer Res. 2021;27(14):3926\u201335. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2790.","journal-title":"Clin Cancer Res"},{"key":"4547_CR70","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/4909544","volume":"2022","author":"R Dong","year":"2022","unstructured":"Dong R, Chen S, Lu F, Zheng N, Peng G, Li Y, et al. Models for predicting response to immunotherapy and prognosis in patients with gastric cancer: DNA damage response genes. BioMed Res Int. 2022;2022:4909544. https:\/\/doi.org\/10.1155\/2022\/4909544.","journal-title":"BioMed Res Int"},{"issue":"1","key":"4547_CR71","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s40425-019-0647-4","volume":"7","author":"L Fancello","year":"2019","unstructured":"Fancello L, Gandini S, Pelicci PG, Mazzarella L. Tumor mutational burden quantification from targeted gene panels: major advancements and challenges. J Immunother Cancer. 2019;7(1):183. https:\/\/doi.org\/10.1186\/s40425-019-0647-4.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"4547_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-04859-8","volume":"22","author":"X Li","year":"2024","unstructured":"Li X, Xiong F, Hu Z, Tao Q, Yang Y, Qiao X, et al. A novel biomarker associated with EBV infection improves response prediction of immunotherapy in gastric cancer. J Transl Med. 2024;22(1):90. https:\/\/doi.org\/10.1186\/s12967-024-04859-8.","journal-title":"J Transl Med"},{"issue":"3","key":"4547_CR73","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004080","volume":"10","author":"Y Bai","year":"2022","unstructured":"Bai Y, Xie T, Wang Z, Tong S, Zhao X, Zhao F, et al. Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer. J Immunother Cancer. 2022;10(3):e004080. https:\/\/doi.org\/10.1136\/jitc-2021-004080.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"4547_CR74","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010024","volume":"13","author":"J Veas Rodriguez","year":"2025","unstructured":"Veas Rodriguez J, Pi\u00f1ol M, Sorolla MA, Parisi E, Sorolla A, Santacana M, et al. Comprehensive immunophenotyping of gastric adenocarcinoma identifies an inflamed class of tumors amenable to immunotherapies. J Immunother Cancer. 2025;13(3):e010024. https:\/\/doi.org\/10.1136\/jitc-2024-010024.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"4547_CR75","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1158\/2159-8290.CD-12-0361","volume":"3","author":"JN Wu","year":"2013","unstructured":"Wu JN, Roberts CW. ARID1A mutations in cancer: another epigenetic tumor suppressor? Cancer Discov. 2013;3(1):35\u201343. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0361.","journal-title":"Cancer Discov"},{"issue":"5","key":"4547_CR76","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41591-018-0012-z","volume":"24","author":"J Shen","year":"2018","unstructured":"Shen J, Ju Z, Zhao W, Wang L, Peng Y, Ge Z, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556\u201362. https:\/\/doi.org\/10.1038\/s41591-018-0012-z.","journal-title":"Nat Med"},{"issue":"1","key":"4547_CR77","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04758-4","volume":"21","author":"W Tang","year":"2023","unstructured":"Tang W, Li G, Lin Q, Zhu Z, Wang Z, Wang Z. Multiplex immunohistochemistry defines two cholesterol metabolism patterns predicting immunotherapeutic outcomes in gastric cancer. J Transl Med. 2023;21(1):887. https:\/\/doi.org\/10.1186\/s12967-023-04758-4.","journal-title":"J Transl Med"},{"key":"4547_CR78","doi-asserted-by":"publisher","first-page":"5092505","DOI":"10.1155\/2022\/5092505","volume":"2022","author":"Q Chen","year":"2022","unstructured":"Chen Q, Du X, Hu S, Huang Q. NF-\u03baB-related metabolic gene signature predicts the prognosis and immunotherapy response in gastric cancer. Biomed Res Int. 2022;2022:5092505. https:\/\/doi.org\/10.1155\/2022\/5092505.","journal-title":"Biomed Res Int"},{"issue":"1","key":"4547_CR79","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-023-02730-0","volume":"42","author":"X Li","year":"2023","unstructured":"Li X, Wang Y, Zhai Z, Mao Q, Chen D, Xiao L, et al. Predicting response to immunotherapy in gastric cancer via assessing perineural invasion-mediated inflammation in tumor microenvironment. J Exp Clin Cancer Res. 2023;42(1):206. https:\/\/doi.org\/10.1186\/s13046-023-02730-0.","journal-title":"J Exp Clin Cancer Res"},{"key":"4547_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2024.148796","volume":"928","author":"G Li","year":"2024","unstructured":"Li G, Li Z, Shen J, Ma X, Zheng S, Zheng Y, et al. Identifying and validating angiogenesis-related genes remodeling tumor microenvironment and suppressing immunotherapy response in gastric cancer. Gene. 2024;928:148796. https:\/\/doi.org\/10.1016\/j.gene.2024.148796.","journal-title":"Gene"},{"key":"4547_CR81","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1149989","volume":"14","author":"H Yang","year":"2023","unstructured":"Yang H, Zou X, Yang S, Zhang A, Li N, Ma Z. Identification of lactylation related model to predict prognostic, tumor infiltrating immunocytes and response of immunotherapy in gastric cancer. Front Immunol. 2023;14:1149989. https:\/\/doi.org\/10.3389\/fimmu.2023.1149989.","journal-title":"Front Immunol"},{"issue":"5","key":"4547_CR82","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-008927","volume":"12","author":"Z Han","year":"2024","unstructured":"Han Z, Zhang Z, Yang X, Li Z, Sang S, Islam MT, et al. Development and interpretation of a pathomics-driven ensemble model for predicting the response to immunotherapy in gastric cancer. J Immunother Cancer. 2024;12(5):e008927. https:\/\/doi.org\/10.1136\/jitc-2024-008927.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"4547_CR83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cpan.2024.11.001","volume":"21","author":"J Chen","year":"2024","unstructured":"Chen J, Lin A, Luo P. Advancing pharmaceutical research: a comprehensive review of cutting-edge tools and technologies. Curr Pharm Anal. 2024;21(1):1\u201319. https:\/\/doi.org\/10.1016\/j.cpan.2024.11.001.","journal-title":"Curr Pharm Anal"},{"issue":"1","key":"4547_CR84","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.cpan.2024.12.001","volume":"21","author":"Z Wang","year":"2024","unstructured":"Wang Z, Zhao Y, Zhang L. Emerging trends and hot topics in the application of multi-omics in drug discovery: a bibliometric and visualized study. Curr Pharm Anal. 2024;21(1):20\u201332. https:\/\/doi.org\/10.1016\/j.cpan.2024.12.001.","journal-title":"Curr Pharm Anal"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04547-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04547-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04547-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T12:56:06Z","timestamp":1786884966000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04547-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,16]]},"references-count":84,"alternative-id":["4547"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04547-7","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,16]]},"assertion":[{"value":"1 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The manuscript does not contain clinical studies or patient data.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"this manuscript is a literature review and does not involve human participants, patient data, orclinical samples. Therefore, informed consent is not applicable.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}